Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2073677 Target Snapshot

Solute carrier family 22 member 11 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
58Compounds
62Assays
9Approved Drugs
29.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Solute carrier family 22 member 11 shows approved-linked disease relevance led by gout. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9NSA0. Start with gout, then reuse UniProt Q9NSA0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with gout, then reuse UniProt Q9NSA0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
gout

Solute carrier family 22 member 11 shows approved-linked disease relevance led by gout. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with gout because it currently carries approved-linked support. Linked drugs include PROBENECID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Solute carrier family 22 member 11 as ChEMBL target CHEMBL2073677, mapped to UniProt Q9NSA0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Solute carrier family 22 member 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2073677
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NSA0
Solute carrier family 22 member 11
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Solute carrier family 22 member 11 is the right protein anchor across sources, using UniProt Q9NSA0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why gout is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSolute carrier family 22 member 11
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ9NSA0
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSolute carrier family 22 member 11
UniProt AccessionQ9NSA0
Component TypeProtein
Sequence Length550 aa

Solute carrier family 22 member 11

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Solute carrier family 22 member 11, mapped to UniProt Q9NSA0. Sequence length is 550 aa.

Mapped IDQ9NSA0
Review nameSolute carrier family 22 member 11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Solute carrier family 22 member 11 shows approved-linked disease relevance led by gout. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
gout
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Late clinical Phase III
cystitis
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Late clinical Phase III
infection
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Late clinical Phase III
male infertility
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Late clinical Phase III
obesity
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Late clinical Phase III
urinary tract infection
1 linked drug · 1 direct · 1 efficacy
Linked drugPROBENECID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with gout because it currently carries approved-linked support. Linked drugs include PROBENECID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasegout
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC5013.0
KI16.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL617 6.7 Ki 200.0 Approved
CHEMBL1146 5.94 Ki 1140.0 Clinical
CHEMBL1435 5.76 Ki 1740.0 Approved
CHEMBL2105720 5.69 IC50 2030.0 Approved
CHEMBL161 5.62 Ki 2380.0 Approved
CHEMBL507674 5.55 Ki 2800.0 Approved
CHEMBL316157 5.44 Ki 3630.0 Approved
CHEMBL1730 5.21 Ki 6150.0 Approved
CHEMBL3929544 5.07 IC50 8500.0 Preclinical
CHEMBL3924161 5.03 IC50 9400.0 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
5
5.5
0
6.0
1
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CEPHALOTHIN
CHEMBL617
Approved 1974
Properties Compare Identifier
Assay Landscape

Assay Landscape

62
Total Assays
15
Tested Compounds
3
Assay Types
Functional — 53 assays, 15 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 53 15 5.3
Binding — 6 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 7 4.9
cell-based format 1 1 5.7
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine